Arcus Biosciences Inc
RCUS9.100USD
-0.060-0.66%
交易中 （美東）報價延遲15分鐘
963.69M總市值
虧損本益比TTM
關於 Arcus Biosciences Inc 公司
Arcus Biosciences, Inc. 是一家臨牀階段生物製藥公司，致力於爲癌症患者開發差異化分子和聯合療法。該公司涉及一系列研究產品，這些產品正處於臨牀開發階段，其先進分子是一種針對肺癌和胃腸道癌症的抗 TIGIT 抗體。該公司有大約七個臨牀項目，重點關注靶點，包括 TIGIT、PD-1、腺苷 A2a 和 A2b 受體、CD73、CD39、HIF-2a 和 AXL。該公司正在共同開發四種研究產品，包括 zimberelimab（Arcuss 抗 PD-1 分子）、domvanalimab（Arcuss 抗 TIGIT 抗體）、etrumadenant（Arcuss 腺苷受體拮抗劑）和 quemliclustat（Arcuss CD73 抑制劑）。該公司正致力於開展 domvanalimab 與抗 PD-1 抗體 zimberelimab 聯合治療的 II 期和 III 期開發計劃，用於治療肺癌和胃腸癌等多種疾病。
公司簡介
公司代碼RCUS
公司名稱Arcus Biosciences Inc
上市日期Mar 15, 2018
CEODr. Terry J. Rosen, Ph.D.
員工數量627
證券類型Ordinary Share
年結日Mar 15
公司地址3928 Point Eden Way
城市HAYWARD
上市交易所NYSE Consolidated
國家United States of America
郵編94545-3719
電話15106946200
網址https://arcusbio.com/
公司代碼RCUS
上市日期Mar 15, 2018
CEODr. Terry J. Rosen, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
Dr. Andrew Perlman, M.D., Ph.D.
Dr. Andrew Perlman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard Markus, M.D., Ph.D.
Mr. Richard Markus, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kathryn E. Falberg
Ms. Kathryn E. Falberg
Independent Director
Independent Director
--
--
Ms. Jennifer A. Jarrett
Ms. Jennifer A. Jarrett
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
業務USD
名稱
營收
佔比
License and development services revenue
20.00M
71.43%
Collaboration revenue
8.00M
28.57%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
License and development services revenue
20.00M
71.43%
Collaboration revenue
8.00M
28.57%
股東統計
更新時間: 6月8日 週日
更新時間: 6月8日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Gilead Sciences Inc
29.68%
BlackRock Institutional Trust Company, N.A.
9.14%
The Vanguard Group, Inc.
6.30%
Woodline Partners LP
4.84%
Fidelity Management & Research Company LLC
3.90%
Other
46.14%
持股股東
持股股東
佔比
Gilead Sciences Inc
29.68%
BlackRock Institutional Trust Company, N.A.
9.14%
The Vanguard Group, Inc.
6.30%
Woodline Partners LP
4.84%
Fidelity Management & Research Company LLC
3.90%
Other
46.14%
股東類型
持股股東
佔比
Corporation
29.68%
Investment Advisor
27.66%
Hedge Fund
17.50%
Investment Advisor/Hedge Fund
12.68%
Individual Investor
5.36%
Venture Capital
2.82%
Research Firm
1.88%
Pension Fund
0.62%
Bank and Trust
0.29%
Other
1.52%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
438
104.36M
98.58%
+5.92M
2025Q1
461
106.23M
100.41%
+7.59M
2024Q4
458
92.45M
92.67%
-8.14M
2024Q3
459
92.17M
107.84%
+6.16M
2024Q2
456
90.82M
107.03%
+3.48M
2024Q1
456
91.60M
108.07%
-2.14M
2023Q4
455
76.21M
102.30%
-15.07M
2023Q3
450
76.35M
103.06%
-17.88M
2023Q2
441
78.29M
107.10%
-16.66M
2023Q1
448
78.22M
107.14%
-13.36M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Gilead Sciences Inc
31.42M
29.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.68M
9.14%
+1.14M
+13.37%
Mar 31, 2025
The Vanguard Group, Inc.
6.68M
6.3%
+1.30M
+24.15%
Mar 31, 2025
Woodline Partners LP
5.13M
4.84%
+1.60M
+45.50%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.12M
3.9%
+404.71K
+10.88%
Mar 31, 2025
State Street Global Advisors (US)
3.70M
3.49%
+702.75K
+23.47%
Mar 31, 2025
Point72 Asset Management, L.P.
2.87M
2.71%
+870.82K
+43.62%
Mar 31, 2025
Rosen Terry Jay
2.57M
2.43%
-472.90K
-15.53%
Mar 01, 2025
Suvretta Capital Management, LLC
2.56M
2.42%
+1.98M
+344.48%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.72M
1.63%
+19.78K
+1.16%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
1.2%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
ALPS Medical Breakthroughs ETF
0.58%
Tema Oncology ETF
0.5%
Invesco S&P SmallCap Health Care ETF
0.39%
Invesco S&P SmallCap 600 Pure Growth ETF
0.31%
SPDR S&P Biotech ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.12%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.08%
iShares S&P Small-Cap 600 Growth ETF
0.08%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比1.2%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.78%
ALPS Medical Breakthroughs ETF
佔比0.58%
Tema Oncology ETF
佔比0.5%
Invesco S&P SmallCap Health Care ETF
佔比0.39%
Invesco S&P SmallCap 600 Pure Growth ETF
佔比0.31%
SPDR S&P Biotech ETF
佔比0.2%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.12%
Vanguard S&P Small-Cap 600 Growth Index Fund
佔比0.08%
iShares S&P Small-Cap 600 Growth ETF
佔比0.08%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
